WAWellgner Fernandes Oliveira Amador

Wellgner Fernandes Oliveira Amador

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Wellgner Fernandes Oliveira Amador has a total of 62 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Correction: Negative pressure wound therapy in primary closure surgeries for pilonidal disease: a meta-analysis

    by Marcelo Albuquerque Barbosa Martins, Wellgner Fernandes Oliveira Amador, Rachid Eduardo Noleto da Nobrega Oliveira, João Ricardo Duda, Fernanda Bellotti Formiga

  • Open Access

    Primary Sclerosing Cholangitis Recurrence After Liver Transplantation: A Systematic Review and Updated Meta‐Analysis

    by Isabelle Castro Vitor, Milena Ramos Tomé, Wellgner Fernandes Oliveira Amador, Igor Boechat Silveira, Marina de Assis Bezerra Cavalcanti Leite, Pedro Robson Costa Passos, Valbert Oliveira Costa Filho, Mariana Macambira Noronha, Yohanna Idsabella Rossi, Guilherme Grossi Lopes Cançado, et al.

    Background and Aims: Primary sclerosing cholangitis (PSC) is an immune‐mediated cholestatic liver disease. Liver transplantation (LT) remains the only definitive treatment for patients with advanced disease. However, recurrence of PSC (rPSC) after LT is still a significant clinical challenge. The aim of this study was to assess the prevalence and incidence of rPSC following transplantation and to identify factors associated with its occurrence. Methods: We conducted a systematic review and meta‐analysis of observational cohorts by searching PubMed, Embase and Cochrane for studies. Statistical analyses were conducted using R, applying a random‐effects model with 95% confidence intervals. Results: Twenty‐nine studies were included, comprising 4682 patients who underwent LT for PSC (63.7% male). Most data originated from Europe (51.7%) and North America (29.2%), with additional cohorts from Asia (13.7%), South America (2.8%) and Oceania (2.6%). The worldwide pooled prevalence of rPSC was 18.66% (95% CI 15.33–22.52; I 2 = 84%) between 1980 and 2024. As for the worldwide pooled incidence, rPSC occurred at 26.04 per 1000 person‐years (95% CI 19.30–32.78; I 2 = 76.1%). The continent with the highest rPSC prevalence was Oceania with 30.65% (95% CI 23.17–39.29; I 2 = 13.8%) and South America had the highest incidence with 39.97 per 1000 person‐years (95% CI 25.42–54.51). Younger recipient age (mean difference [MD] = 5.16 years, 95% CI 4.13–6.19; I 2 = 51.3%), male sex (risk ratio [RR] = 0.92, 95% CI 0.87–0.98; I 2 = 0%), post‐LT cyclosporine use (RR = 0.56, 95% CI 0.42–0.76; I 2 = 0%), acute rejection (RR = 0.64, 95% CI 0.49–0.83) and de novo IBD (RR = 0.63, 95% CI 0.40–0.99; I 2 = 0%) were associated with an increased risk of recurrence. Conclusions: Prevalence and incidence of rPSC post‐LT varied according to continents. Younger recipient age, male sex, de novo IBD, cyclosporine use post‐LT and acute rejection episodes were associated with a higher risk of recurrence. Trial Registration: PROSPERO ID: CRD420250645485


  • Open Access

    Omadacycline for community-acquired infections: A systematic review and single-arm meta-analysis

    by Wellgner Fernandes Oliveira Amador, Cainã Araújo Saraiva, Pandora Eloá Oliveira Fonseca, Sávio Benvindo Ferreira

    Introducción. Las infecciones adquiridas en la comunidad suponen una carga considerable para los sistemas de salud y son causadas por diversos agentes patógenos que pueden presentar distintos grados de gravedad. El aumento de la resistencia microbiana complica el tratamiento, lo que destaca la necesidad de nuevas terapias. La omadaciclina, un nuevo antibiótico, tiene una actividad de amplio espectro contra agentes patógenos tanto grampositivos como gramnegativos, en particular los implicados en infecciones adquiridas en la comunidad.Objetivo. Evaluar la eficacia y seguridad de la omadaciclina para el tratamiento de infecciones adquiridas en la comunidad.Materiales y métodos. Se buscaron estudios aleatorizados y no aleatorizados sobre omadaciclina para infecciones adquiridas en la comunidad, en PubMed, Embase y Cochrane, sin restricciones de tiempo. Los resultados primarios fueron el éxito clínico al final del tratamiento y la evaluación posterior al tratamiento. Los resultados secundarios incluyeron el riesgo de eventos adversos. El análisis estadístico se hizo con el software R. Resultados. Se analizaron datos de diez estudios que incluyeron 1666 pacientes y que abordaron infecciones como neumonía, infecciones de heridas, celulitis, abscesos importantes, úlceras de las extremidades inferiores, erisipela, cistitis e infecciones óseas o articulares. El análisis mostró una tasa de éxito clínico del 90 % (1138 de 1264 pacientes; IC95%: 88 - 91) al final del tratamiento y del 84 % (1288 de 1534 pacientes; IC95%: 82 - 86) postratamiento. Ocurrieron eventos adversos en el 45 % de los casos (747 de 1662; IC95%: 32 - 59), con un 18 % que experimentaron problemas gastrointestinales (181 de 1008; IC95%: 13 - 24). La tasa de mortalidad fue del 0 % (0,8%) (13 pacientes; IC95%: 0 - 1).Conclusión. La omadaciclina es una opción prometedora para el tratamiento de las infecciones adquiridas en la comunidad.

  • Negative pressure wound therapy in primary closure surgeries for pilonidal disease: a meta-analysis

    by Marcelo Albuquerque Barbosa Martins, Wellgner Fernandes Oliveira Amador, Rachid Eduardo Noleto da Nobrega Oliveira, João Ricardo Duda, Fernanda Bellotti Formiga

    Primary closure with negative pressure wound therapy (NPWT) has been investigated in patients with sacrococcygeal pilonidal sinus to enhance healing and reduce recurrence. To address existing controversies, we conducted a systematic review and meta-analysis comparing primary closure with NPWT versus non-NPWT (control) for treatment of pilonidal disease. PubMed, Embase, and Cochrane Library databases were searched from inception to December 2024 to identify studies comparing NPWT versus control in primary closure surgeries in pilonidal sinus. Statistical analyses were performed using R Software with a random-effects model. Six studies with a total of 479 patients were included, of whom 164 (34.2%) underwent NPWT. NPWT had an association with lower pain score 24 h postoperative (MD − 0.65 points; 95% CI − 0.81 to − 0.50), shorter return time to activities (MD − 2.57 days; 95% CI − 3.74 to − 1.4). However, there was no difference between groups in the time of wound closure (MD − 18.94; 95% CI − 41.68 to 3.80), rate of wound dehiscence (RR 1.03; 95% CI 0.50 to 2.14), hospital length of stay (MD − 3.05; 95% CI − 15.77 to 9.67), infection rates (RR 0.38; 95% CI 0.05 to 2.84), recurrence rates (RR 0.54; 95% CI 0.07 to 4.48), and pain 6 h post-operative, which showed a borderline trend favoring NPWT but did not reach statistical significance (MD − 1.19; 95% CI − 2.38 to 0.01). NPWT appears to shorten time to resume normal activities and pain 24 h postoperatively. Despite these promising results, more randomized clinical trials are needed for greater analysis.


    • 9 January 2026
      • Vol. 62, e25056
    Open Access

    EFFECTIVENESS AND SAFETY OF SELECTIVE IL-12/23 RECEPTOR ANTAGONISTS IN MODERATE TO SEVERE ULCERATIVE COLITIS: A SYSTEMATIC REVIEW, META-ANALYSIS AND TRIAL SEQUENTIAL ANALYSIS.

    by Wellgner Fernandes Oliveira Amador, Isabelle Castro Vitor, Milena Ramos Tomé, Diogo Delgado Dotta, Rodrigo V Motta

    Selective IL-12/23p40 receptor antagonists (IL-12/23RA) show promise for treating moderate to severe ulcerative colitis (UC), but their efficacy and safety are not fully understood. Objective: This systematic review and meta-analysis assess the effectiveness and safety of IL-12/23RA in UC. A systematic search of PubMed, Embase, Cochrane, and ClinicalTrials.gov was performed in December 2024. Randomized controlled trials (RCTs) comparing IL-12/23RA to placebo in moderate to severe UC were included. Outcomes included clinical and endoscopic remission, response rates, and adverse events (AEs). Risk ratios (RR) and mean differences (MD) with 95% confidence intervals (CI) were pooled using a random-effects model. Nine RCTs (3,808 patients in the induction phase; 1,734 in the maintenance phase) were analyzed. IL-12/23RA enhanced clinical remission (induction: RR 2.63; 95%CI 2.05-3.36; maintenance: RR 1.99; 95%CI 1.63-2.44; all P<0.01) and endoscopic remission (induction: RR 2.36; 95%CI 1.70-2.20; maintenance: RR 1.96; 95%CI 1.63-2.37; all P<0.01). IL-12/23RA reduced serious AE in the induction phase (RR 0.40; 95%CI 0.27-0.69; P<0.01), while there was no difference during maintenance (RR 0.75; 95%CI 0.31-1.84; P=0.53). No differences were observed in overall AEs or specific AEs like headache or nasopharyngitis. Trial sequential analysis confirmed sufficient sample size for clinical endpoints. IL-12/23RA showed superior effectiveness and similar safety when compared to placebo in moderate to severe UC.

  • Open Access

    Effect of Perioperative Benzodiazepine Use on Postoperative Delirium in Patients Undergoing Cardiac Surgery: A Systematic Review and Meta‐Analysis

    by Marcela da Silva Kazitani Cunha, Hilária Saugo Faria, Lucas Mendes Barbosa, Leonardo Reischoffer Do Nascimento, Carlos Henrique de Oliveira Ferreira, Karlos Daniell Araújo dos Santos, Lucas Cael Azevedo Ramos Bendaham, Acza Kalica Buarque da Silva, Altair Pereira de Melo Neto, Wellgner Fernandes Oliveira Amador, et al.

    Introduction: Cardiac surgery anesthesia is associated with risks such as postoperative delirium (POD) and stress‐related responses. Benzodiazepines have been used perioperatively to reduce anxiety and promote hemodynamic control. However, their use may increase the risk of delirium, particularly in older adults. This systematic review and meta‐analysis aims to evaluate the impact of perioperative benzodiazepine use on the incidence of POD in patients undergoing cardiac surgery. Methods: We systematically searched for randomized controlled trials (RCTs) and observational studies comparing benzodiazepines with placebo or nonbenzodiazepine drugs in adults undergoing cardiac surgery. The primary outcome was POD incidence; secondary outcomes included mini‐mental state examination (MMSE), ICU length of stay, and time to extubation. For dichotomous outcomes, odds ratios (ORs) with 95% confidence intervals (CIs) were calculated, while mean differences (MDs) were used for continuous outcomes. Analyses were performed using R 4.4.3. Results: Eight studies were included, comprising 36,301 patients, of whom 20,747 (68.5%) received benzodiazepines. Follow‐up ranged from 1 day to 12 months. There were no significant differences between groups in the incidence of POD (OR 1.05; 95% CI: 0.88 to 1.25; p = 0.55; I 2 = 83%). Similarly, there were no significant difference in MMSE score (MD ‐0.11; 95% CI: −3.17 to 2.95; p = 0.94; I 2 = 70%), ICU length of stay (MD 4.72 h; 95% CI: −1.37 to 10.80; p = 0.13; I 2 = 99%), and time to extubation (MD ‐0.53 h; 95% CI: −2.16 to 1.09; p = 0.52; I 2 = 72%). Conclusion: Perioperative benzodiazepine use was not significantly associated with POD or with secondary outcomes in adults undergoing cardiac surgery.

  • Evaluation of GLP-1 receptor agonists in obstetrics and perinatal outcomes: A systematic review and meta-analysis

    by Bruna Benigna Sales Armstrong, Ana Clara Pimenta Servidoni, Giovanna Cristina de Castro Martin, Guilherme Franceschini Machado, Wellgner Fernandes Oliveira Amador, Abdelrahman Yousif


  • Open Access

    Effectiveness and Safety of Selective IL-23 Receptor Antagonists in Moderate to Severe Ulcerative Colitis: A Systematic Review, Meta-Analysis and Trial Sequential Analysis

    by Wellgner Fernandes Oliveira Amador, Isabelle Castro Vitor, Milena Ramos Tome, Diogo Delgado Dotta, Rodrigo V Motta

    Selective interleukin-23 receptor antagonists (IL-23RA) show promise for treating moderate to severe ulcerative colitis (UC) but their efficacy and safety are not fully understood. We performed a systematic review and meta-analysis of randomized controlled trials comparing IL-23RA with placebo in moderate to severe UC. Outcomes included clinical and endoscopic remission, response rates, and adverse events. Nine trials including 3808 patients in the induction phase and 1734 in the maintenance phase were analyzed. IL-23RA improved clinical remission (induction risk ratio 2.63, 95 percent confidence interval 2.05-3.36; maintenance 1.99, 95 percent confidence interval 1.63-2.44) and endoscopic remission (induction 2.36, 95 percent confidence interval 1.70-2.20; maintenance 1.96, 95 percent confidence interval 1.63-2.37). IL-23RA reduced serious adverse events in the induction phase (0.40, 95 percent confidence interval 0.27-0.69) with no difference during maintenance (0.75, 95 percent confidence interval 0.31-1.84). No significant differences were observed in overall adverse events or specific events such as headache or nasopharyngitis. Trial sequential analysis confirmed sufficient sample size for clinical endpoints. IL-23RA showed superior effectiveness and similar safety compared with placebo in moderate to severe UC.

  • Intravenous Iron Therapy in Patients With Heart Failure With Preserved Ejection Fraction: A Systematic Review and Meta-Analysis

    by Juan Pinilla, Sebastian Jaramillo, Ravi Patel, Nyree Nava, Wellgner Fernandes Oliveira Amador, Miguel Angel Samaniego, Kalgi Modi

  • Pharmacological Treatments for Menopausal Vasomotor Symptoms: A Systematic Review and Bayesian Network Meta-Analysis of Efficacy and Safety

    by Wellgner Fernandes Oliveira Amador, Cainã Araújo Saraiva, Mariano Gallo Ruelas, Ivo Queiroz, Asad Iqbal, Giovana de Souza Gaio, Juan Alejandro Pinilla Alarcón, Joao Roberto De Sa